Search

Bristol-Myers Squibb Co.

Cerrado

SectorSanidad

66.81 -1.72

Resumen

Variación precio

24h

Actual

Mínimo

66.56

Máximo

66.92

Métricas clave

By Trading Economics

Ingresos

638M

3.3B

Ventas

1.5B

13B

P/B

Media del Sector

14.74

56.659

BPA

2.04

Rentabilidad por dividendo

3.76

Margen de beneficios

25.561

Empleados

32,500

EBITDA

1.3B

4.9B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+0.18% upside

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

3.76%

2.18%

Próximas Ganancias

29 oct 2026

Próxima Fecha de Ex Dividendo

2 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8.9B

137B

Apertura anterior

68.53

Cierre anterior

66.81

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

272 / 339 Clasificación en Healthcare

Bristol-Myers Squibb Co. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 sept 2026, 22:14 UTC

Correlated Moves
Social Media

Bristol-Myers Squibb Co shares are lower in after-market trading following the FDA's withdrawal of Krazati's accelerated approval for colorectal cancer.

3 sept 2026, 21:51 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, declining since Thursday's close amid a broader market rally and no specific company news.

2 sept 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. Broader market sentiment is affected by rising oil prices amid U.S.-Iran tensions.

1 sept 2026, 23:06 UTC

Correlated Moves

Bristol-Myers Squibb shares declined after market close, mirroring a broader downturn in the pharmaceutical sector amid rising oil prices and inflation concerns.

31 ago 2026, 20:07 UTC

News
Social Media
Correlated Moves
Event

Bristol-Myers Squibb shares are higher following positive long-term data on Camzyos presented at the European Society of Cardiology Congress, showing significant patient improvements.

28 ago 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rebounding from three consecutive lower sessions with no specific news identified.

27 ago 2026, 19:36 UTC

Bristol-Myers Squibb shares are lower today amid broader market concerns over rising inflation and potential Federal Reserve interest rate hikes.

26 ago 2026, 23:16 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the decline following a routine session.

25 ago 2026, 23:21 UTC

Correlated Moves

Bristol-Myers Squibb Co shares are lower in after-market trading, influenced by a decline in the pharmaceutical sector and falling crude oil prices.

24 ago 2026, 23:41 UTC

Bristol-Myers Squibb shares are trading lower in after-market hours amid weak market conditions and heightened geopolitical tensions affecting overall investor sentiment.

21 ago 2026, 20:02 UTC

Social Media

Bristol-Myers Squibb Co is higher today following reports of a collaboration with Chai on antibody discovery, enhancing its drug development capabilities.

20 ago 2026, 20:01 UTC

News

Bristol-Myers Squibb shares are lower amid a significant decline in the Pharmaceuticals sub-sector, despite recent FDA approval for its multiple myeloma drug.

19 ago 2026, 23:21 UTC

Bristol-Myers Squibb Co shares are higher in after-market hours, fluctuating between a low of -0.28% and a high of 0.50% since Wednesday's close.

18 ago 2026, 19:46 UTC

Social Media

Bristol-Myers Squibb is using AI tools to cut clinical trial development times, trading higher amid positive market sentiment surrounding these advancements.

17 ago 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market trading amid broader market concerns and unusual selling pressure, though no specific news was identified.

14 ago 2026, 20:06 UTC

Social Media
News
Event

Bristol-Myers Squibb shares are lower after FDA approval of Zenbexus due to concerns over its $29,500 pricing, which may dampen market sentiment.

13 ago 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

12 ago 2026, 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

11 ago 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rising from earlier gains and positioned above their 20-day moving average.

10 ago 2026, 23:51 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. The decline follows three consecutive sessions of gains amid shifting labor market sentiment.

8 ago 2026, 00:01 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, continuing a decline since Friday's close despite being above the 20-day moving average.

7 ago 2026, 23:06 UTC

Bristol-Myers Squibb shares lower in after-market trading, despite maintaining a position above the 20-day moving average. No specific news was identified.

6 ago 2026, 23:26 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, influenced by broader market trends and a stronger U.S. Dollar amid rising jobless claims.

5 ago 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. No specific news was identified to explain the movement.

4 ago 2026, 23:16 UTC

Bristol-Myers Squibb Co. shares gained in after-market trading, reflecting a modest uptick of 0.20% and remaining above their 20-day moving average.

3 ago 2026, 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

31 jul 2026, 19:16 UTC

News
Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

30 jul 2026, 22:51 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

29 jul 2026, 23:36 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

28 jul 2026, 20:06 UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. previsión

Precio Objetivo

By TipRanks

0.18% repunte

Estimación a 12 Meses

Media 66.94 USD  0.18%

Máximo 80 USD

Mínimo 40 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

8

Comprar

10

Mantener

1

Vender

Sentimiento

By Acuity

272 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat